Isavuconazole 🆚 Voriconazole for invasive aspergillosis: same treatment success ✅, similar adverse events 🤕, but voriconazole is 5x more used and way cheaper 💰.

💉 Among PWID in LA & Denver, 38% had ≥1 skin abscess in the past 3 months. Strong associations:.• Assisted injection.• ≥3 injections/day.• Syringe licking.Findings support urgent need for safer injection education.

Influenza in high-risk patients: 19% developed bacterial complications, 17% needed antibiotics. Oseltamivir & umifenovir showed similar efficacy, but oseltamivir had more GI side effects.

Ugandan cohort: 21% hyperuricemia prevalence among PLWH on dolutegravir-based ART; alcohol use = key modifiable risk. More focus needed on lifestyle interventions.

Selective reporting works! 🦠🔬 A quasi-experimental study showed that tailoring AST reports for HECK-Yes (moderate-risk ampC) Enterobacterales boosted appropriate antibiotics within 24h by 24% (62% ➡️ 86%; p=0.01) without harming outcomes.

🦠 MDR P. aeruginosa study found- .✔️ ESBL (23.8%), AmpC (20.5%), MBL (13.5%) detected. ✔️ Risk ↑ with prolonged stay (OR 11.2) & immunosuppressants (OR 6.7). risk factors: long hospital stay & prior immunosuppression.

📣 Special Collection — Call for Papers! 🧫🦠.Share your insights on Combination Therapies for Complex Infections: synergy, resistance, PK/PD & precision use. 🧪 Deadline: Sept 15, 2025.Details at

Staph aureus bacteremia still deadly. β-lactam combos: faster clearance, variable survival benefit, AKI risk.

📌 New study finds 33% of Hep B treatment-naïve patients already harbor primary antiviral resistance mutations—mostly rtV207M. ⚠️ No clear link to genotype or clinical factors.👉 Genotypic screening crucial to guide therapy and prevent treatment failure.

From barrier to trigger: skin microbiota guard us but can also drive disease when balance falters. Latest review explores mechanisms and emerging microbiome therapies.

🚨 Submission Open! 🚨.🦠 Antimicrobial Resistance Mechanisms & Therapeutic Options for Difficult-to-treat Nosocomial Pathogens 🌍.📅 Deadline: Dec 31, 2025.📚 Submissions are now welcome!.For full details, check out the link.

TB care ≠ just antibiotics. In Ghana, many patients had persistently poor QOL after 6 months. Mental health, stigma, & social support must be addressed.

COVID-19 unmasked plastic bronchitis in a man with HIV & Kaposi sarcoma. Not all dyspnea in PWH is infection—think rare complications.

📚Submissions open for the collection -Case Reports from the Global South: Learning from Low- to Mid-Resource Settings.🗓️ Deadline: November 28, 2025 💡 Showcase innovation,resilience, & local expertise in resource-limited settings. @andhen25.

🧫 In a microbiome sub-study of patients on antibiotics:.💊 Ampicillin, piperacillin-tazobactam,&meropenem →.• ↑ Enterococcus faecium colonization.• ↑ ARGs (blaTEM-1A, blaSHV-100, blaCMY-18).• ↓ beneficial anaerobes (Clostridium, Bifidobacterium).

Among adults with HIV in Zambia, kidney impairment (eGFR <60) affected 10.7%. Risk was significantly higher in older adults and those on DTG + TDF/3TC regimens. 🩺 Monitoring renal function in PLWH on ART is critical.

🚨 Study from Malawi: Among people with HIV admitted to hospital, inability to walk unaided predicted in-hospital death as well as the full WHO or qSOFA scores (AUROC ~0.68–0.71).

🚨 Rising drug-resistant #TB in Tanzania threatens SDG3 progress. Using Bayesian zero-inflated Poisson models, this study maps high-risk areas & identifies key drivers: sex, age, HIV status & prior TB treatment.

Is there a “weekend effect” in ICU care for infected patients?.🇯🇵 Analysis from Japanese ICUs (DIANA cohort) finds no significant difference in ICU discharge or mortality at 14/28 days between weekend vs weekday admissions.

By 2050, antimicrobial resistance (AMR) may cause 10 million deaths annually. Not just superbugs—resistance is rising in fungi, viruses, and parasites. This review highlights the escalating threat of AMR.